TRAW

#4787
Traws Pharma, Inc. - Common Stock
0.5 7 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.57
0.57
Jahresspanne
0.43
3.25
Tagesänderung
-3.39%
Monatliche Änderung
+16.33%
6 month change
-65.66%
Jahresänderung
-65.03%
Vorheriger Schlusskurs
0.5 7
Open
0.5 7
Tief
0.5 7
Hoch
0.5 7
Volumen
1
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Traws Pharma, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K

Traws Pharma, Inc. current report, Q3 FY2023

Full document

Business Context and Reporting Period

This Form 8-K was filed by Onconova Therapeutics, Inc. (trading symbol: ONTX) on July 21, 2023. The filing reports on corporate governance events rather than financial performance. Note: The request metadata referenced "Traws Pharma, Inc.," but the filing text explicitly identifies the registrant as Onconova Therapeutics, Inc.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the status of the company's Annual Meeting of Stockholders.

Material Changes and Events

  • Quorum Failure: On July 21, 2023, the company called its Annual Meeting to order but failed to achieve a quorum due to an insufficient number of shares present or represented by proxy.
  • Meeting Adjournment: The Annual Meeting was adjourned and rescheduled for August 10, 2023, at 9:00 a.m. Eastern Daylight Time.
  • Logistics: The reconvened meeting will be held virtually at the same location as the original meeting. The record date for stockholders remains May 23, 2023.
  • Proxy Validity: Proxies submitted prior to the original meeting remain valid for the reconvened meeting unless properly changed or revoked.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, management commentary on business outlook, or specific risk factors beyond the operational risk of failing to secure a quorum for shareholder voting. The primary contingency addressed is the need for additional time to solicit votes from stockholders to ensure a quorum is met at the reconvened meeting.

Investor Verification Checklist

  • Verify the outcome of the reconvened Annual Meeting scheduled for August 10, 2023.
  • Confirm whether the company successfully achieved a quorum at the rescheduled date.
  • Review the results of the shareholder proposals that were pending at the time of the adjournment.
  • Check for any subsequent filings regarding the appointment of directors or executive compensation if those were items on the agenda.